Page 3 - Dr Reddys
TCS, Infosys, and Dr Reddy's shares hit fresh record highs
Dr Reddy's rallied 5 per cent to Rs 4,524 today, surging 12 per cent in the past two trading days after the company reported a strong operational performance in Q1FY21.
 "TCS, Infosys, and Dr Reddy's shares hit fresh record highs")
India's coronavirus drug market set for price war as firms ready launches
Sources say Cipla-BDR's favipiravir will be at least 30 per cent cheaper than Glenmark's price of Rs 103 per tablet. Cipla did not confirm.
 "India's coronavirus drug market set for price war as firms ready launches")
Covid-19 crisis: Made-in-India remdesivir may come by end of June
Currently, the drug is allowed for "restricted emergency use" on severely ill hospitalised Covid patients in India.
 "Covid-19 crisis: Made-in-India remdesivir may come by end of June")
Revised Wockhardt deal boosts prospects of Dr Reddy's India business
The company, according to its new strategy, is focusing on growing its India-based branded products
 "Revised Wockhardt deal boosts prospects of Dr Reddy's India business")
Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business
The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period
 "Dr Reddy's Q4 PBT up 22% at Rs 714 cr on buoyant US, European business")
Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit
The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards
 "Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit")
Dr Reddy's Labs hits over 4-year high, surges 62% from March low
Analysts believe Dr Reddy's US business, which has been facing revenue pressure, is likely to rebound with new product launches and the gradual normalization of price erosion in its key products.
 "Dr Reddy's Labs hits over 4-year high, surges 62% from March low")
Dr Reddy's board approves borrowing of Rs 2,000 cr through multiple routes
DRL's board also the approved sale of the Contract Development and Manufacturing Organisation(CDMO) division of Custom Pharmaceutical Services (CPS), on a slump sale basis
 "Dr Reddy's board approves borrowing of Rs 2,000 cr through multiple routes")
USFDA seeks voluntary action at Dr Reddy's Andhra Pradesh facility
Shares of Dr Reddy's Laboratories on Friday closed 0.55 per cent down on the BSE
 "USFDA seeks voluntary action at Dr Reddy's Andhra Pradesh facility")
Diabetes to be our focus in India, US: Wockhardt's Habil Khorakiwala
Wockhardt is present in emerging markets like Mexico, Brazil with insulins
 "Diabetes to be our focus in India, US: Wockhardt's Habil Khorakiwala")
New launches, regulatory go-ahead key triggers for Dr Reddy's
Sales in the US, its biggest market, accounting for 37 per cent of revenues, were up 8 per cent year-on-year (YoY) and 12 per cent sequentially, led by five new launches
 "New launches, regulatory go-ahead key triggers for Dr Reddy's")
Top headlines: Air India's 100% stake sale; 1,000 frauds in 5 years at UCBs
From government announcing a 100 per cent stake sale in Air India to a new case of Coronavirus in India here are today's top headlines
 "Top headlines: Air India's 100% stake sale; 1,000 frauds in 5 years at UCBs")
Stock recommendation from Prabhudas Lilladher: Buy Dr Reddy's, GAIL
The stock of Dr. Reddy's has been on a gradual rise with positive indicators supporting the momentum and currently has given a breakout above the previous peak of 3,000
 "Stock recommendation from Prabhudas Lilladher: Buy Dr Reddy's, GAIL")
Dr Reddy's falls 5% as rival firm beats Co to US FDA approval for EluRyng
Rival firm Amneal Pharma has received approval for generic birth-control product NuvaRing from the US Food and Drug Administration.
 "Dr Reddy's falls 5% as rival firm beats Co to US FDA approval for EluRyng")
Technical calls by Religare Broking: Buy Dr Reddy's Lab, Ramco Cements
Weekly Technical Recommendations by Religare Broking Ltd.
Dr Reddy's gets 4 observations from USFDA for Srikakulam plant
Drug major Dr Reddy's on Saturday said it has received four observations from the US health regulator USFDA for its facility at Srikakulam in Andhra Pradesh. The audit of the company's API Srikakulam Plant (SEZ) by the United States Food and Drug Administration (USFDA) was completed on Friday, the Hyderabad-based pharma major said in a regulatory filing. Dr Reddy's further said that it would address the four concerns within the stipulated timeline. "The audit of our API Srikakulam Plant (SEZ), Andhra Pradesh, by the USFDA, has been completed on October 25, 2019. We have been issued a Form 483 with four observations," said Dr Reddy's. It further said: "We will address them comprehensively within the stipulated timeline." As per the US health regulator, "an FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and ...
Dr Reddy's Laboratories recalls anti-ulcer drug ranitidine from US market
The recall comes after USFDA's caution note alerting patients and healthcare professionals that NDMA was found in certain samples of ranitidine
 "Dr Reddy's Laboratories recalls anti-ulcer drug ranitidine from US market")
Dr Reddy's Labs shines among pharma stocks, wins investor confidence
The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year
 "Dr Reddy's Labs shines among pharma stocks, wins investor confidence")
Dr Reddy's halts worldwide supply of Ranitidine drug after probe by USFDA
Ranitidine is an Over-The-Counter (OTC) and prescription drug which decreases the amount of acid created by the stomach
 "Dr Reddy's halts worldwide supply of Ranitidine drug after probe by USFDA")
Regulatory worries, price erosion may pull down Dr Reddy's US revenues
Repeat observations for an approved facility are an indication of consistent regulatory challenges for the company, says an analyst with a foreign brokerage
 "Regulatory worries, price erosion may pull down Dr Reddy's US revenues")
